Lower Urinary Tract Symptoms and Erectile Dysfunction in Prostate Hyperplasia: New Technologies for Early Diagnosis
Keywords:
benign prostatic hyperplasia, lower urinary tract symptoms, erectile dysfunction, electronic questionnaireAbstract
The article presents the possibilities of using electronic questionnaires for early diagnosis and selection of treatment method for lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) due to benign prostatic hyperplasia (BPH). The severity of LUTS and ED in patients with BPH was assessed using the electronic questionnaire based on the Telegram platform. The results of the patient questionnaire were assessed using an electronic program depending on the type of questionnaire completion - independently, with the help of a doctor, using an electronic application.
References
Alyaev, Yu.G. Urology. Russian clinical guidelines / Edited by Yu.G. Alyaev, P.V. Glybochko, D.Yu. Pushkar. - M.: GEOTAR-Media, 2016. - 496 p.
Alyaev, Yu.G. Drug treatment of lower urinary tract symptoms in men. The role of uroselectivity in drug selection / Yu.G. Alyaev, Z.K. Gadzhieva, L.M. Rapoport, Yu.B. Kazilov // Andrology and genital surgery. - 2014. - No. 1. - P. 6-15.
Apolikhin O.I., Komarova V.A., Nikushina A.A., Sivkov A.V. Diseases of the prostate gland in the Russian Federation: statistical data 2008-2017. Experimental and Clinical Urology. 2019;(2):4-13. https://doi.org/10.29188/2222-8543-2019-11-2-4-12
Giyasov Sh.I. et al. The role of systematization of postoperative complications in assessing the effectiveness and safety of surgical methods for the treatment of benign prostatic hyperplasia. Urology 2022. - No. 3. - P.83-91.
R.R. Gafarov, Sh.I. Giyasov Unified criteria of postoperative complications in assessing the effectiveness and safety of surgical methods for the treatment of benign prostate hyperplasia. Uzbek medical journal. – 2022. – Vol.3. - No. 4. – P.24-33.
Giyasov Sh.I., Gafarov R.R., Mukhtarov Sh.T. Assessment of the effectiveness and safety of different surgical methods for the treatment of benign prostate hyperplasia by adaptation of the Clavien-Dindo classification// American Journal of Medicine and Medical Sciences 2022; 12(2): 96-103.
Ergakov, D.V. Dysfunction of urination in men, benign prostatic hyperplasia and primary approaches to the treatment of lower urinary tract symptoms / D.V. Ergakov, A.G. Martov // Therapy. - 2020. - No. 8. - P. 192-198.
Ergakov, D.V. Symptoms of the lower urinary tract after transurethral resection of the prostate / D.V. Ergakov, A.G. Martov, A.S. Andronov, N.A. Baykov // Urology. - 2020. - No. 1. - P. 103-109.
Gafarov R.R., Allazov S.A., Giyasov Sh.I. Laser enucleation – a new word in surgical treatment of benign prostatic hyperplasia.Dr. Akhbrotnomasi 2019;1:132-137.
Kogan, M.I., Medvedev, V.L., Mikhailov, I.V., Shornikov, P.V., Efremov, M.E. Ways to solve diagnostic problems caused by nocturia in patients with benign prostatic hyperplasia / M.I. Kogan // Innovative Medicine of Kuban. - 2019. - v.4. - p. 40-46.
Kuzmenko, A.V., Kuzmenko, V.V., Gyaurgiev, T.A. Efficiency of fesoteradine in patients after transurethral resection of the prostate gland / A.V. Kuzmenko // Urology. - 2019.- No. 1. - p. 52-55.
Korneev, I.A. Epidemiology of urination disorders in men of the Russian Federation / I.A. Korneev, T.A. Alekseeva, M.I. Kogan, D.Yu. Pushkar // Urology. - 2016. - No. 2. - P. 70-75.
Laurent, O.B. Efficacy and safety of using Omnic Ocas for patients with lower urinary tract symptoms due to benign prostatic hyperplasia in routine clinical practice in the Russian Federation (prospective multicenter observational program) / O.B. Laurent, A.A. Seregin // Urology. - 2018. - No. 2. - P. 38-74.
Martov, A.G., Ergakov, D.V., Turin, D.E., Andronov, A.S. Bipolar and laser enucleation of large benign prostatic hyperplasia / A.G. Martov // Urology. - 2020.- No. 1.- p.59-63.
Mustafayev, A.T., Kyzlasov, P.S., Dianov, M.P., et al. Surgical treatment of benign prostatic hyperplasia: past and present / A.T. Mustafayev // Urological News.-2019.- vol. 9.-№ 1.-p. 47-56
Peshekhonov, K.S., Shpilenya, E.S., Burlaka, O.O. The importance of the pharmacoeconomic approach in choosing treatment for prostatic hyperplasia / K.S. Peshekhonov // Urological news. - 2019. - v. 9. - No. 4. - P. 59-72.
Pushkar, D.Yu., Bernikov, A.N., Khodyreva, L.A. et al. Quality of life of patients with lower urinary tract symptoms after transurethral resection of benign prostatic hyperplasia / D.Yu. Pushkar // Urology - 2018. - No. 1. - p. 53-61.
Popov, S.V. The state of copulative function in patients after holmium laser enucleation of benign prostatic hyperplasia / S. V. Popov, I. N. Orlov, E. A. Grin [et al.] // Urological News. - 2019. - Vol. 9, No. 2. - P. 17-22.
Rasner, P.I., Pushkar, D.Yu. Symptoms of the lower urinary tract: drug treatment of symptoms of the accumulation phase (clinical lecture) /P.I. Rasner// Consilium Medicum.- 2016.- 18 (7).- p. 30-36.
Tolkushin, A.G., Smirnova, A.V., Ermolaeva, T.N., Davydovskaya, M.V. Fixed and separate combination of solifenacin and tamsulosin for urination disorders associated with benign prostatic hyperplasia: choice based on price and value comparison / A.G. Tolkushin // High-quality clinical practice. - 2019. - No. 1. - P. 12-18.
Naumov, A.V. Diseases of aging men: focus on the prostate gland / A.V. Naumov, I.D. Alekseev, S.A. Budylev // Emergency doctor. - 2011. - No. 6. - P. 31-39.
Athanasopoulos A, Chapple C, Fowler C, Gratzke C, Kaplan S, Stief C, Tubaro A. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol. 2011; 60(1):94-105. https://doi.org/10.1016/j. eurouro.2011.03.054
Barendrecht MM, Koopmans RP, et al. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: cardiovascular system. BJU Int 2005; 95:19–28.
Joseph C, Presti Jr. Benign prostatic hyperplasia incidence and epidemiology. 2007.
Demir O, Akgul K, Akar Z. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009; 1:29-34.
Shah MI, Butler M, Bramley T, et. al. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. Curr Med Res Opin. 2007; 23(2):417-426.
Koff W, Bertero E, Pinheiro G, et al. A randomized, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia. Program and abstracts of the American Urological Association Annual Meeting. May 21–26. 2005. San Antonio, Texas. Abstract 1643.
Hellstrom W, Smith W, Sikka C. Effects of alpha-blockers on ejaculatory function in normal subjects. Program and abstracts of the American Urological Association Annual Meeting. May 21–26. 2005. San Antonio, Texas. Abstract 874.
Marks LS. Preventing BPH Disease in asymptomatic Men at risk of progression. UAU. April/May 2006.
Marberger M, Harkaway R, de la Rosette J. Optimizing the medical management of benign prostatic hyperplasia. Eur Urol 2004;45(4): 411–19.
Montorsi F, Moncada I. Safety and tolerance of treatment for BPH. Euro Urol 2006; 5(Suppl.):1005.
Netto Júnior NR, de Lima ML. The influence of patient education level on the International Prostatic Symptom Score. J Urol. 1995; 154(1):97-9. https://doi.org/10.1097/00005392-199507000-00034
Van der Walt CL, Heyns CF, Groeneveld AE, Edlin RS, van Vuuren SP. Prospective comparison of a new visual prostate symptom score versus the international prostate symptom score in men with lower urinary tract symptoms. Urology. 2011; 78 (1):17-20. https://doi.org/10.1016/j. urology.2011.01.065
